hrp0086p1-p640 | Growth P1 | ESPE2016

Analysis of Correlation between Stem Cells (CD133+/CD45+ and CD133+/CD45) and Anthropometric Parameters of Children with Growth Hormone/Primary Insulin-Like Growth Factor 1 Deficiency

Sawicka Beata , Moniuszko Marcin , Grubczak Kamil , Singh Paulina , Radzikowska Urszula , Mikłasz Paula , Dębrowska Milena , Bossowski Artur

Introduction: Hematopoetic progenitor stem cells (HSCs, CD133+/CD45+) and very small embryonic-like stem cells (VSELs, CD133+/CD45−) can differentiate into specific immune cells. Some studies suggest that levels of HSCs and VSELs change during therapy with growth hormone (GH) or insulin-like growth factor 1 (IGF-1). GH deficiency (GHD), an endocrine disease connected with insufficient production of GH by pituitary gland, is tre...

hrp0082p2-d1-412 | Growth Hormone | ESPE2014

ALS Deficiency due to a Novel and Two Already Described IGFALS Gene Mutations in an Unusual Non Consanguineous Family: Two Compound Heterozygous (Father and Son) and Two Heterozygous Carriers (Brother and Mother)

Scaglia Paula , Keselman Ana , Martucci Lucia , Karabatas Liliana , Ballerini Maria Gabriela , Domene Sabina , Johanna Acosta , Jasper Hector , Domene Horacio

Introduction: Complete ALS deficiency (ALS-D), caused by inactivating mutations in both IGFALS gene alleles, presents severe IGF1 and IGFBP3 deficiencies associated to moderate growth retardation.Aim: To characterize the molecular defect in a family where the index case and his father presented short stature and IGF1 and IGFBP3 deficiencies.Methods: IGF1, IGFBP3, and GH serum levels were determined by CLIA, ALS by ELISA an...

hrp0082p2-d2-546 | Puberty and Neuroendocrinology (1) | ESPE2014

Kallmann Syndrome: Diagnosis in Paediatric Age

Machado Angela , Oliveira Maria Joao , Borges Teresa , Cardoso Helena , Fonseca Paula , Ribeiro Luis , Goncalves Catarina , Lemos Manuel

Background: Kallmann syndrome (KS) is a rare clinical entity, characterized by the association of hipogonadotropic hypogonadism and hypo/anosmia, with an estimated prevalence of 1:8000 in males and 1:40 000 in females.Method: Retrospective study of cases of KS diagnosed in paediatric age. Genetic analysis was performed by PCR and DNA sequencing of KAL1, FGFR1, GNRHR, GNRH1, PROK2, PROKR2, KISS1R, TAC3, TACR3, and FGF8 genes.Results...

hrp0094p1-134 | Growth Hormone and IGFs A | ESPE2021

Starting recombinant human growth hormone treatment at an early age improves adherence and catch-up growth in patients with growth disorders, and highlights the importance of the new guideline on referral of short children to paediatric care

van Dommelen Paula , Zoonen Renate van , Vlasblom Eline , Wit Jan M. , Beltman Maaike , Arnaud Lilian , Koledova Ekaterina ,

Background: The new preventive child health care guideline for referral of short/tall children facilitates early detection of growth disorders. Understanding the impact of early treatment initiation on recombinant human growth hormone (rhGH) adherence and catch-up growth can support the use of the guideline.Aim: To evaluate the impact of age at rhGH treatment start on adherence (≥85% vs <85% of prescribed doses...

hrp0094p2-72 | Bone, growth plate and mineral metabolism | ESPE2021

ACAN gene skeletal dysplasia (short size syndrome, with or without advanced bone age and early onset osteoarthritis)

Aguilar Riera Cristina , Arciniegas Larry , Murillo Valles Marta , Ros Pena Andrea , Alvarez Paula Fernandez , Clemente Maria , Yeste Diego ,

Aggrecan is a structural glycoprotein of the extracellular matrix of cartilage present in the articular cartilage, growth plate and cartilage of the intervertebral disc. Biallelic pathogenic variants are the cause of aggrecan type spondyloepiphyseal dysplasia (OMIM#612813) while the presence of heterozygous pathogenic variants determine Kimberley type spondyloepiphyseal dysplasia (OMIM#608361) and short stature associated or not with acceleration of bone maturation and early o...

hrp0092p1-328 | Diabetes and Insulin (2) | ESPE2019

Creating a Neural Network Model Based on Glycemic Variability Indices to Predict the Degree of Compensation for Type 1 Diabetes

Koshmeleva Marina , Samoilova Juliya , Kobyakova Olga , Oleynik Oxana , Brazovskii Konstantin , Nazarenko Valeriya , Filippova Tatiyana , Podchinenova Dariya

Actuality: Standard methods for determining the compensation of the disease don't always reliably reflect the level of the glycemic control of the patient, which leads to decompensation diabetes and reduce the quality and duration of life for patients. Evaluation of glycemic variability indices allows the physicians to predict the risk of developing life-threatening conditions and compensate the diabetesAim: To condu...

hrp0086fc6.5 | Syndromes: Mechanisms and Management | ESPE2016

Pathogenic Copy Number Variants are Frequently Identified in Children with Short Stature of Unknown Etiology

Canton Ana , Homma Thais , Furuya Tatiane , Roela Rosimeire , Arnhold Ivo , Jorge Alexander

Background: The etiology of short stature is heterogeneous, often encompassing complex genetic disorders of difficult diagnosis. Analysis of chromosomic copy number variants (CNVs) has been demonstrating the important role of these genomic imbalances in population diversity and human disease.Objective and hypotheses: To analyze the frequency and describe novel submicroscopic chromosomal CNVs in a group of patients with short stature of unknown cause....

hrp0086p2-p541 | Fat Metabolism and Obesity P2 | ESPE2016

Non-Medicament Treatment of Severe Obese Children, Using the One-Year Courses

Zagrebaeva Olga , Solntsava Anzhalika , Yemelyantsava Tatsiana

Background: It is hard to treat severe obese children only with diet and physical activity, psychological interventions are need.Objective and hypotheses: To examine the differences between courses of non-medicament treatment of severe obese children.Method: We examined 32 pubertal severe obese children BMI 31.2±0.8 kg/m2, 13.5±0.3 years. The newel (in Belarus) course of non-medicament treatment of obesity (die...

hrp0092fc14.4 | GH and IGF4 | ESPE2019

Once-Weekly TransCon hGH vs. Daily hGH in Pediatric Growth Hormone Deficiency: The Phase 3 heiGHt Trial

Vlachopapadopoulou Elpis , Aghajanova Elena , Chertok Elena , Korpal-Szczyrska Maria , Giorgadze Elene , Kovalenko Tatiana , Maniatis Aristedes , Thornton Paul , Hofman Paul , Song Wenjie , Shu Aimee , Karpf David , Beckert Michael , Leff Jonathan

Background: TransCon hGH is a sustained-release prodrug in development as a long-acting GH for children with growth hormone deficiency (GHD). TransCon hGH consists of a parent drug, growth hormone (hGH; somatropin), that is transiently bound to a carrier via a TransCon linker. The carrier extends hGH circulation time in the body and fully active hGH is released over one week at physiologic pH and temperature. Unlike other molecules in development, TransCon hGH...

hrp0095p1-538 | Multisystem Endocrine Disorders | ESPE2022

Capillary Hyperglycemia in Infants - A manifestation of endocrinological urgency, or not.

de Assis Galan Camila , Isabel Scheidt Maria , Cristina Pedroso de Paula Leila , Vanessa de Lima Silva Elis , Simão Medeiros Leonardo , de Oliveira Poswar Fabiano

Capillary hyperglycemia in critically ill infants is a situation with numerous interfering factors, from acute illnesses to concomitant use of medications and may or may not be a manifestation of endocrinological urgency. Clinical case: Female patient, 2 months old, with failure to thrive, hepatomegaly without cholestasis, polyuria and compensated metabolic acidosis. On admission, capillary blood glucose levels above 200 mg/dL were measured even without concomitant use of cort...